Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance
Personalis, Inc. (PSNL)
Last personalis, inc. earnings: 3/25 04:01 pm
Check Earnings Report
Company Research
Source: Business Wire
Lung cancer coverage, supported by data from the landmark TRACERx collaboration, follows recent approval in breast cancer, providing access to Medicare patients. FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced Medicare coverage for the company’s NeXT Personal molecular residual disease (MRD) test for surveillance of patients with Stage I to III non-small cell lung cancer (NSCLC).This coverage determination is grounded in clinical evidence generated through the company’s collaboration with the TRACERx (TRAcking Cancer Evolution through therapy (Rx)) consortium. Data from this world-renowned longitudinal study, recently published in Cell, demonstrated NeXT Personal's ability to identify residual disease with high accuracy, validating the test’s clinical performance in lung cancer.Lung cancer remains the leading cause of cancer death in the United States, with an estimated ~230,000 new cases diagn
Show less
Read more
Impact Snapshot
Event Time:
PSNL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PSNL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PSNL alerts
High impacting Personalis, Inc. news events
Weekly update
A roundup of the hottest topics
PSNL
News
- Personalis, Inc. (PSNL): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors [Yahoo! Finance]Yahoo! Finance
- Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid TumorsBusiness Wire
- Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceBusiness Wire
- Personalis (NASDAQ:PSNL) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
PSNL
Earnings
- 11/4/25 - Beat
PSNL
Sec Filings
- 1/29/26 - Form SCHEDULE
- 1/23/26 - Form 4
- 1/22/26 - Form 144
- PSNL's page on the SEC website